RedHill Biopharma (RDHL) Return on Capital Employed (2014 - 2023)

RedHill Biopharma (RDHL) has 10 years of Return on Capital Employed data on file, last reported at 234.47% in Q2 2023.

• On a quarterly basis, Return on Capital Employed rose 876690.0% year-over-year to 234.47% in Q2 2023; TTM through Jun 2023 was 234.47%, a 876690.0% increase from a year earlier, with the FY2025 full-year figure at 321.15%, down 70702.0% from the prior year.
• Return on Capital Employed for Q2 2023 stood at 234.47%, down from 108.68% in the prior quarter.
• Over the last five years, Return on Capital Employed for RDHL reached as high as 108.68% in Q4 2022 and fell as low as 9001.37% in Q2 2022.
• Historically, Return on Capital Employed has averaged 982.89% across 5 years, with a median of 58.17% in 2021.
• Across the five-year window, Return on Capital Employed tumbled 905954 bps in 2022 and surged 876690 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 92.79% in 2019, then plunged by 32 bps to 62.82% in 2020, then tumbled by 226 bps to 79.32% in 2021, then soared by 237 bps to 108.68% in 2022, then sank by 316 bps to 234.47% in 2023.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 234.47% in Q2 2023, 108.68% in Q4 2022, and 9001.37% in Q2 2022.